Mirum Pharmaceuticals Inc - Asset Resilience Ratio
Mirum Pharmaceuticals Inc (MIRM) has an Asset Resilience Ratio of 6.89% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Mirum Pharmaceuticals Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Mirum Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Mirum Pharmaceuticals Inc.
Liquid Assets Composition Over Time
This chart breaks down Mirum Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Mirum Pharmaceuticals Inc (MIRM) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $61.35 Million | 6.89% |
| Total Liquid Assets | $61.35 Million | 6.89% |
Asset Resilience Insights
- Limited Liquidity: Mirum Pharmaceuticals Inc maintains only 6.89% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mirum Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Mirum Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Mirum Pharmaceuticals Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Mirum Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.28% | $86.64 Million | $842.81 Million | +1.66pp |
| 2024-12-31 | 8.62% | $57.81 Million | $670.75 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $646.62 Million | -- |
| 2022-12-31 | 35.06% | $123.72 Million | $352.91 Million | -7.43pp |
| 2021-12-31 | 42.49% | $125.20 Million | $294.65 Million | +5.24pp |
| 2020-12-31 | 37.26% | $89.73 Million | $240.86 Million | -34.10pp |
| 2019-12-31 | 71.36% | $104.69 Million | $146.71 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $51.98 Million | -- |
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more